Understand the significant growth trajectory of the GLP-2 Drug Class segment, which is expected to reach $5.4 Billion by 2030 with a CAGR of a 23.2%. The Growth Hormone Drug Class segment is also set to grow at 21% CAGR over the analysis period.
Short Bowel Syndrome (SBS) Market
Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Short Bowel Syndrome (SBS) - Global Strategic Business Report" has been added to offering.
The global market for Short Bowel Syndrome (SBS) was valued at USD 2 Billion in 2024 and is projected to reach USD 6.4 Billion by 2030, growing at a CAGR of 21.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the Short Bowel Syndrome (SBS) market is driven by several factors, including the rising incidence of SBS and other gastrointestinal disorders, technological advancements in parenteral nutrition, enzymes, and pharmacological treatments, and the increasing use of human growth hormone, glucagon-like peptide-2 (GLP-2) agonists, and dietary supplements in SBS management. The development of orphan drugs, biologics, and novel surgical techniques with enhanced efficacy, safety, and convenience is driving market adoption among hospitals, specialty clinics, and home healthcare providers.
The focus on enhancing multidisciplinary, patient-centric care models, self-management, and remote monitoring is expanding the market reach among pediatric, adult, and post-surgical patients. The growing use of SBS therapies in combination with regenerative medicine, digital health, and artificial intelligence, coupled with the demand for personalized and nutrition-based SBS care solutions, is creating new opportunities for market growth. Additionally, the increasing investments in R&D for gene therapy, stem cell therapy, and microbiome-based treatments are further supporting market expansion.
The report analyzes the Short Bowel Syndrome (SBS) market, presented in terms of market value (USD Thousand). The analysis covers the key segments and geographic regions outlined below.
Drug Class (GLP-2, Growth Hormone, Glutamine, Other Drug Classes); Mode of Administration (Parenteral, Oral).
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
-
Market Growth: Understand the significant growth trajectory of the GLP-2 Drug Class segment, which is expected to reach $5.4 Billion by 2030 with a CAGR of a 23.2%. The Growth Hormone Drug Class segment is also set to grow at 21% CAGR over the analysis period.
-
Regional Analysis: Gain insights into the U.S. market, valued at $553.3 Million in 2024, and China, forecasted to grow at an impressive 20.1% CAGR to reach $934.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
